ClinicalTrials.gg
RecruitingNCT06168006RecoveryUpdated Feb 17, 2026

Exercise Training Using an App on Physical Cardiovascular Function Individuals With Post-covid-19 Syndrome

An interventional study of Exercise and Control in Post-Acute COVID-19 Syndrome, sponsored by University of Nove de Julho. Recruiting at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by University of Nove de Julho · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Post-Acute COVID-19 Syndrome with a site in Brazil — 9 open to participants now, 10 under way, 2 of them phase 3. Post-Acute COVID-19 Syndrome · Brazil.

Planned enrollment
6th of 18
60 · median 57
Started
2024
with 3 others
No phase
12 of 21
5 open now
Registered
14th of 21
by date
Lead sponsor
3 of 21
University of Nove de Julho

Among the 21 studies in Post-Acute COVID-19 Syndrome with a site in Brazil, this one is the 6th largest by planned enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2024, is one of 12 with no phase, and was the 14th registered.

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

9 of the 21 studies in Post-Acute COVID-19 Syndrome with a site in Brazil are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Post-Acute COVID-19 Syndrome with a site in Brazil, or all of them as a file.
02

Study summary

The aim of this study is to assess the effect of a physical exercise program via a mobile application on functional parameters in individuals with post-COVID-19 syndrome. This is a clinical trial involving 60 individuals with post-COVID syndrome who will be randomly assigned to either a control group (physical activity guideline) or an experimental group (app-based training).

03

Conditions studied

  • Post-Acute COVID-19 Syndrome

Keywords

  • exercise
  • mobile app
  • physical function
  • cardiovascular function
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Laboratory diagnosis of COVID-19
  • Fatigue ≥ 8 points on the Chalder Scale and/or dyspnea 2-4 on the Modified Medical Research Council
  • Have access to a smartphone
  • Have no for exercise practice
  • Have ability to sit and stand and maintain balance while standing
  • Have preserved cognitive function
  • Have no risk of falls according to the Morse Fall Scale
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Exercise intervention

    The subjects randomized to this group will perform three app-based training sessions per week for 12 weeks, each session lasting a maximum of 40 minutes.

    Behavioral: Exercise

  • Sham comparator
    Control intervention

    This group will receive a booklet with exercise instructions, and will be recommended the same frequency and duration of exercise as the experimental group

    Behavioral: Control

Interventions

  • BehavioralExercise

    The experimental group will undergo an exercise program using the Recovery App. Participants will receive guidance from researchers about the functionality of the app. The Recovery App includes flexibility, strength, and aerobic training exercises, aiming for a progressive intensity and volume over the weeks.

    Also known as: Rehabilitation, Physical activity, Endurance, Resistance exercises

  • BehavioralControl

    They will receive an exercise booklet based on the Brazilian Physical Activity Recommendations (MINISTRY OF HEALTH, 2021), which recommend 150 minutes of physical activity for adults and seniors.

06

What researchers measure

Primary outcomes

  1. Change from baseline in 6 min-walk test distance at 12 weeks

    The 6-minute walk test performed in a 30-meter corridor, measured in meters

    Time frame: Baseline and 12 weeks

  2. Change from baseline in Glittre test at 12 weeks

    The test consists in rise from a chair, carry a weighted backpack, walk 10 meters, climb stairs, move objects between shelves (1 kg each), and return. They perform tasks sequentially, transferring items up and down shelves. The route is retraced, ending by sitting back in the initial chair, measured in seconds

    Time frame: Baseline and 12 weeks

  3. Change from baseline in sit and stand test at 12 weeks

    The test consists in rising from a chair as many times as possible within 30 seconds, measured in number of repetitions

    Time frame: Baseline and 12 weeks

  4. Change from baseline in Post-Covid Functional Scale at 12 weeks

    The Post-COVID-19 Functional Status Scale assesses limitations following SARS-CoV-2 infection, measured as a score

    Time frame: Baseline and 12 weeks

Secondary outcomes

  1. Change from baseline in Patient Functional Scale at 12 weeks

    The Patient Functional Scale allows individuals to identify 3 to 5 important activities they consider themselves unable to perform or are having difficulty with due to their condition, measured in a score

    Time frame: Baseline and 12 weeks

  2. Change from baseline in Motor Evoked Potential at 12 weeks

    The cortical excitability of the quadriceps motor area will be measured using Motor Evoked Potential results in microvolts (µV) using the Transcranial Magnetic Stimulation equipment model MagPro R20 (MagVenture, Denmark) with the parabolic coil model MMC-140-II, measured in kgf

    Time frame: Baseline and 12 weeks

  3. Change from baseline in Modified Medical Research Dyspnea Scale at 12 weeks

    This scale comprises five items, allowing the patient to select the item that corresponds to how much their dyspnea limits their daily life activities, measured as a score

    Time frame: Baseline and 12 weeks

  4. Change from baseline in Chalder Physical Fatigue Scale at 12 weeks

    Comprising eight specific statements about physical fatigue to confirm its presence or absence, measured as a score

    Time frame: Baseline and 12 weeks

  5. Change from baseline in De Paul Symptom Questionnaire at 12 weeks

    The questionnaire evaluate the symptoms of fatigue in different conditions, measured as a score

    Time frame: Baseline and 12 weeks

  6. Change from baseline in Quality of Life at 12 weeks

    To assess quality of life, the 12-Item Short-Form Health Survey will be used, consisting of twelve items that evaluate eight different dimensions influencing quality of life, measured as a score

    Time frame: Baseline and 12 weeks

  7. Change from baseline in Frailty and Sarcopenia at 12 weeks

    Frailty will be assessed using the Tilburg Frailty Indicator, while sarcopenia will be evaluated through the Sarcopenia Form questionnaire, both measured as a score

    Time frame: Baseline and 12 weeks

  8. Change from baseline in Anxiety and Depressive Symptoms at 12 weeks

    Levels of anxiety and depression will be assessed using the Hospital Anxiety and Depression Scale, measured as a score

    Time frame: Baseline and 12 weeks

  9. Change from baseline in Pain at 12 weeks

    Assessed using the Numeric Pain Rating Scale, measured as a score

    Time frame: Baseline and 12 weeks

  10. Change from baseline in Movement Behavior at 12 weeks

    Movement behavior will be quantified through a motion sensor, measured in minutes

    Time frame: Baseline and 12 weeks

  11. Change from baseline in Barriers to Physical activity at 12 weeks

    Specific questionnaire to assess the most prevalent environmental barriers to physical activity, measured as presence or absence

    Time frame: Baseline and 12 weeks

  12. Post assessment of Exercise Adherence Assessment Scale

    Adherence to exercise interventions will be obtained with the Adherence Assessment Scale

    Time frame: 12 weeks

  13. Change from baseline in Blood Pressure at 12 weeks

    The clinical resting blood pressure will be assessed using automatic blood pressure monitoring equipment (HEM-7113, OMRON®, Brazil), measured in mmHg

    Time frame: Baseline and 12 weeks

  14. Change from baseline in Cardiac Autonomic Modulation at 12 weeks

    Cardiac autonomic modulation will be assessed through heart rate variability using a heart rate monitor, measured in RR intervals

    Time frame: Baseline and 12 weeks

  15. Change from baseline in Blood Flow and Flow-mediated Dilation at 12 weeks

    The measurements of basal blood flow and flow-mediated vasodilation will be obtained through ultrasonography in brachial artery, measured in ml/min or %

    Time frame: Baseline and 12 weeks

  16. Change in Spirometry parameters at 12 weeks

    Changes in Forced vital capacity, forced expiratory volume in the first second, Peak expiratory flow, forced expiratory flow 25-75% and FEV 1 /FVC ratio

    Time frame: Baseline and 12 weeks

Other outcomes

  1. System Usability Scale

    Scale used to assess the individuals' perception of the app's usability in the group submitted to the intervention

    Time frame: 12 weeks

  2. The User Experience Questionnaire

    The questionnaire will be applied in experimental group to collect information regarding the user's overall experience with the app, such as: general perception, overall experience, main barriers, and key difficulties in using the app.

    Time frame: 12 weeks

  3. Focal group

    The focus group will be conducted via video conference with 4 to 10 individuals that participated in experimental group. The guiding questions will aim to understand the user's perception, from usability to effectiveness, including satisfaction and potential improvements to the app.

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The data will be available after the completion of the study and the finalization of the main articles of this projects

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: After the publication of the main articles of the study.

Access criteria: Upon reasonable request

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Jun 2026, 27 months after the start.

Of 232 non-industry interventional studies with no phase under Post-Acute COVID-19 Syndrome, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's planned 27 months is above that.

Counting every sponsor, half of 243 studies reached it within 16 months; a quarter within 7 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2023
First posted
Dec 13, 2023
StartActual
Mar 1, 2024
Primary completionEst.
Jun 30, 2026
CompletionEst.
Jun 30, 2026
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06168006
Responsible party
Raphael Mendes Ritti Dias (Professor, University of Nove de Julho) — Principal investigator
First posted
Dec 13, 2023
Start date
Mar 1, 2024
Primary completion
Jun 30, 2026 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Feb 17, 2026

Study contacts

Raphael Ritti-Dias, PhD
Contact
raphaelritti@gmail.com
+55 19 99940 6878
Fernanda Corrêa, PhD
Contact
fecorrea@uninove.br
+55 11 97344-0380
Fernanda Corrêa, PhD
principal investigator · University of Nove de Julho

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion